MedAdvisor Ltd (ASX: MDR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

MedAdvisor Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $76.14 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 380.72 million
Earnings per share -0.036
Dividend per share N/A
Year To Date Return -50.63%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

MedAdvisor Ltd (ASX: MDR)
Latest News

Digitised heart rate and share price chart with man on ipad in background signifying share price
Technology Shares

Why the MedAdvisor (ASX:MDR) share price jumped 12% today

The medication management platform sees strong growth in the US after its "transformational" acquisition 6 months ago.

Read more »

Three pills with faces showing sad to happy, indicating a rising share price for an ASX pharmaceutical company
Share Market News

The MedAdvisor (ASX:MDR) share price is lifting today. Here’s why

The MedAdvisor (ASX: MDR) share price is surging today after a health program deal was extended. Here are the details.

Read more »

hand on touch screen lit up by a share price chart moving higher
Share Gainers

Why Brickworks, McPherson’s, MedAdvisor, & Premier Investments are storming higher

Brickworks Limited (ASX:BKW) and McPherson's Ltd (ASX:MCP) are two of four ASX shares storming higher on Thursday...

Read more »

medical asx share price represented by doctor giving thumbs up
Share Market News

Why the Medadvisor (ASX:MDR) share price is up 11% this week

The Medadvisor share price is soaring higher this week as the company announced its quarterly report. We take a closer…

Read more »

a doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.
Share Gainers

Why the MedAdvisor (ASX:MDR) share price is pushing higher today

The MedAdvisor Ltd (ASX:MDR) share price is pushing higher on Monday after upgrading its guidance thanks to a stronger than…

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance
Speculative

2 ASX small cap healthcare shares growing quickly

Avita Medical Ltd (ASX:AVH) and this ASX small cap healthcare share have been growing quickly in FY 2021...

Read more »

Share Fallers

Why Afterpay, Goodman, MedAdvisor, & PointsBet shares are dropping lower

Afterpay Ltd (ASX:APT) and Goodman Group (ASX:GMG) shares are two of four dropping lower on Tuesday. Here's why...

Read more »

a smiling doctor looks at her computer screen with medical imaging X-rays on a light screen in the background.
Share Gainers

Why the MedAdvisor (ASX:MDR) share price jumped 9% on Friday

The MedAdvisor Ltd (ASX:MDR) share price was a strong performer on Friday and jumped as much as 9% higher. Here's…

Read more »

MDR ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About MedAdvisor Ltd

MedAdvisor Ltd is engaged in the development and deployment of the MedAdvisor medication and adherence platform. The MedAdvisor platform is focused on improving health outcomes by connecting health professionals with their patients using mobile and web technologies. It has five reporting segments: MedAdvisor; USA, UK, and Asia, and corporate. The company derives most of its revenues from MedAdvisor.

MDR Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 May 2022 $0.20 $0.01 5.13% 46,364 $0.19 $0.20 $0.19
13 May 2022 $0.20 $0.01 5.26% 55,172 $0.20 $0.20 $0.20
12 May 2022 $0.19 $0.01 5.41% 253,366 $0.19 $0.20 $0.19
11 May 2022 $0.19 $0.00 0.00% 114,253 $0.19 $0.19 $0.18
10 May 2022 $0.19 $0.01 5.56% 32,992 $0.18 $0.19 $0.18
09 May 2022 $0.18 $-0.03 -14.29% 244,989 $0.22 $0.22 $0.18
06 May 2022 $0.21 $0.00 0.00% 131,857 $0.21 $0.21 $0.20
05 May 2022 $0.21 $-0.01 -4.65% 67,868 $0.22 $0.22 $0.21
04 May 2022 $0.22 $-0.01 -4.44% 93,215 $0.23 $0.24 $0.22
03 May 2022 $0.23 $0.01 4.65% 206,173 $0.22 $0.24 $0.22
02 May 2022 $0.22 $-0.04 -16.00% 251,455 $0.25 $0.25 $0.22
29 Apr 2022 $0.25 $-0.01 -3.92% 141,397 $0.26 $0.27 $0.25
28 Apr 2022 $0.26 $0.00 0.00% 21,936 $0.26 $0.27 $0.26
27 Apr 2022 $0.26 $-0.01 -3.85% 38,073 $0.27 $0.27 $0.26
26 Apr 2022 $0.26 $0.00 0.00% 18,288 $0.28 $0.28 $0.26
22 Apr 2022 $0.26 $-0.01 -3.77% 6,224 $0.26 $0.26 $0.26
21 Apr 2022 $0.27 $0.01 3.85% 48,969 $0.27 $0.27 $0.26
20 Apr 2022 $0.26 $0.00 0.00% 34,521 $0.26 $0.26 $0.26

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 May 2022 Robert Read Exercise 2 $362,571
Conversion of securities.
09 May 2022 Robert Read Exercise 535 $96,428
Exercise of options.
09 May 2022 Robert Read Buy 535 $96,428
Exercise of options.
09 May 2022 Robert Read Buy 2 $362,571
Conversion of securities.
26 Nov 2021 Robert Read Issued 1 $577,500
Issue of options.
26 Nov 2021 Robert Read Expiry 637 $245,437
Options expired.
26 Nov 2021 Lucas Merrow Issued 750 $288,750
Issue of options.
17 Nov 2021 Jim Xenos Sell 6 $2,464,903
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Robert Read Chief Executive OfficerManaging Director Nov 2015
Mr Read has experience in a range of businesses, including Director of Strategy and Operations in one of the world's pharmaceutical companies, GSK and roles in venture capital and private equity. He has had roles in business consultancy and senior roles in private equity including Director at ANZ Private Equity and Managing Director at Harbert Private Equity, specialising in growth of small and medium sized businesses. He brings a range of skills to the position of CEO - including leadership, sales and marketing, financial performance improvement and a understanding of the requirements to grow businesses. He is a member of Risk and People Committee.
Mr Jim Xenos Non-Executive Director Nov 2015
Mr Xenos brings to the board pharmaceuticals industry experience and market insight and forge over 25 years and have lead teams to drive outcomes. He has a record of delivering market share across national and multinational corporations by creating brand and portfolio strategies, and by introducing new product offerings that leverage go-to market platforms in industry categories. He is a member of the Risk and People Committee.
Mr Joshua Swinnerton CTOExecutive Director Nov 2015
Mr Swinnerton has experience and manage sizeable IT ventures, as a consultant, and as the technical and Operation lead of start-up companies. He led a technology start-up which he also founded and sold into the US as well as raising funds in the US for the company's expansion and managed software development. During this time he gained experience in bridging the gap between technology and business objectives.
Ms Linda Jenkinson Non-Executive ChairmanNon-Executive Director Feb 2022
Ms Jenkinson is an experienced public and private company board director and a company CEO. Ms Jenkinson has worked as a CEO of high growth businesses for over 20 years and has built businesses spanning multiple countries and understands the US, Australian and New Zealand markets. Having co-founded five companies, including Dispatch Management Services (NASDAQ:DMSC), Ms Jenkinson was the third woman to list a company on NASDAQ. Prior to her time as CEO of DMSC and Les Concierges which she ran for 17 years, Ms Jenkinson spent 11 years as a strategy consultant and advisor to Fortune 500 CEOs and boards as a partner with A.T. Kearney and earlier in her career at Price Waterhouse. Ms Jenkinson currently serves as a non-executive director of the Eclipx Group Limited (ASX:ECX) and Harbour Asset Management Limited (NZ). She is Chair of Jaxsta Limited (ASX:JXT) and Guild Trustee Services Pty Limited.
Ms Sandra Margaret Hook Non-Executive Director Jan 2016
Ms Hook has over 25 years experience which include development and implementing business and brands to drive change. She has a record in delivering customer business transformation and transitioning organisations in evolving environments. She brings financial management experience of her career which includes CEO, COO, GM, Marketing Director and Snr Brand Manager with some of Australia's media companies including News Limited, Foxtel, Federal Publishing Company, Murdoch Magazines and Fairfax. She brings a focus on customer digital innovation at Board level. Since 2000 she has served as a non-executive director on listed, public and private companies, and government bodies. She is a trustee of the Sydney Harbour Federation Trust. She is Chair of Risk Committee and a member of People Committee.
Mr Lucas Merrow Non-Executive Director Aug 2021
Mr Merrow has experience in building Medtech enterprises, including Cotiviti/HMS-owned Eliza and the now MedAdvisor-owned Adheris. Having co-founded the MedAdvisor-owned Adheris in 1991, Merrow helped Adheris to grow a pharmacy network in the US with patient access, allowing Adheris to build a blue-chip customer base of many of the world's pharma companies. After Adheris, Mr Merrow cofounded Eliza Corporation which focusing on patient engagement and behaviour change on behalf of health insurers in the US.
Ms RaeAnn Grossman Non-Executive Director Feb 2022
Ms Grossman has experience in US healthcare having previously held senior roles at United Healthcare's Optum, Gorman Group and Censeo. She is currently the EVP of Population Health, Risk Adjustment and Quality at Cotiviti. Cotiviti is a healthcare technology business owned by Private Equity firm Veritas Capital.
Ms Naomi Lawrie General CounselCompany Secretary Aug 2020
-
Naomi Lawrie General CounselCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited 58,898,879 15.61%
Cotiviti Services Llc 43,999,999 11.66%
Ebos Ph Pty Ltd 26,459,627 7.01%
J P Morgan Nominees Australia Pty Limited 23,252,284 6.16%
Kojent Pty Ltd (Kojent A/C) 20,540,866 5.44%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) 15,671,261 4.15%
HSBC Custody Nominees (Australia) Limited 15,109,238 4.00%
Wavey Industries Pty Ltd (Josh Swinnerton Family A/C) 15,008,943 3.98%
Romida Enterprises Pty Ltd (Romida Family A/C) 13,173,035 3.49%
BNP Paribas Noms Pty Ltd (Drp) 9,834,268 2.61%
Provare Pty Ltd (Provare Investment A/C) 3,563,419 0.94%
Peloton Capital Pty Ltd 3,249,216 0.86%
Mishra Enterprises Pty Ltd (Mishra Family A/C) 2,894,737 0.77%
Gread Management Pty Limited (The A G & R R Family A/C) 2,864,285 0.76%
Dr Christopher Harold Benton 2,800,000 0.74%
Allen Group Holdings Pty Ltd 2,631,579 0.70%
Capital Concerns Pty Limited (Logue Family Super Fund A/C) 1,855,344 0.49%
Ethan Allen Investments Pty Ltd (Ethan Allen Invest Unit A/C) 1,773,794 0.47%
Dak Foundation Limited (Dak Foundation A/C) 1,700,000 0.45%
Canonbar Investments Pty Ltd 1,568,964 0.42%

Profile

since

Note